Similar articles for PMID: 25575444

Year	Number of Results
1990	1
1993	3
1996	1
1997	1
1999	1
2000	3
2001	8
2002	9
2003	6
2004	1
2005	1
2006	5
2007	6
2008	5
2009	7
2010	2
2011	3
2012	7
2013	7
2014	5
2015	12
2016	11
2017	8
2018	9
2019	12
2020	14
2021	20
2022	11
2023	1
2024	0

1

A polygenic risk score for breast cancer in women receiving tamoxifen or raloxifene on NSABP P-1 and P-2.

Vachon CM, Schaid DJ, Ingle JN, Wickerham DL, Kubo M, Mushiroda T, Goetz MP, Carlson EE, Paik S, Wolmark N, Nakamura Y, Wang L, Weinshilboum R, Couch FJ. Vachon CM, et al. Breast Cancer Res Treat. 2015 Jan;149(2):517-23. doi: 10.1007/s10549-014-3175-4. Epub 2015 Jan 10. Breast Cancer Res Treat. 2015. PMID: 25575444 Free PMC article.

2

The selective estrogen receptor modulators in breast cancer prevention.

Li F, Dou J, Wei L, Li S, Liu J. Li F, et al. Cancer Chemother Pharmacol. 2016 May;77(5):895-903. doi: 10.1007/s00280-016-2959-0. Epub 2016 Jan 20. Cancer Chemother Pharmacol. 2016. PMID: 26787504 Review.

3

Chemoprevention of breast cancer in the older patient.

Minton SE. Minton SE. Hematol Oncol Clin North Am. 2000 Feb;14(1):113-30. doi: 10.1016/s0889-8588(05)70281-1. Hematol Oncol Clin North Am. 2000. PMID: 10680075 Review.

4

Chemoprevention of breast cancer.

Thomsen A, Kolesar JM. Thomsen A, et al. Am J Health Syst Pharm. 2008 Dec 1;65(23):2221-8. doi: 10.2146/ajhp070663. Am J Health Syst Pharm. 2008. PMID: 19020189 Review.

5

Risk-benefit profiles of women using tamoxifen for chemoprevention.

Nichols HB, DeRoo LA, Scharf DR, Sandler DP. Nichols HB, et al. J Natl Cancer Inst. 2014 Dec 3;107(1):354. doi: 10.1093/jnci/dju354. Print 2015 Jan. J Natl Cancer Inst. 2014. PMID: 25475563 Free PMC article.

6

Exemestane for primary prevention of breast cancer in postmenopausal women.

Zhang Y, Simondsen K, Kolesar JM. Zhang Y, et al. Am J Health Syst Pharm. 2012 Aug 15;69(16):1384-8. doi: 10.2146/ajhp110585. Am J Health Syst Pharm. 2012. PMID: 22855103

7

Chemoprevention for high-risk women: tamoxifen and beyond.

Fabian CJ, Kimler BF. Fabian CJ, et al. Breast J. 2001 Sep-Oct;7(5):311-20. doi: 10.1046/j.1524-4741.2001.21570.x. Breast J. 2001. PMID: 11906441 Review.

8

Effects of high dose raloxifene in selected patients with advanced breast carcinoma.

Gradishar W, Glusman J, Lu Y, Vogel C, Cohen FJ, Sledge GW Jr. Gradishar W, et al. Cancer. 2000 May 1;88(9):2047-53. doi: 10.1002/(sici)1097-0142(20000501)88:9<2047::aid-cncr10>3.0.co;2-e. Cancer. 2000. PMID: 10813716

9

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER Jr, Wade JL 3rd, Robidoux A, Margolese RG, James J, Lippman SM, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N; National Surgical Adjuvant Breast and Bowel Project (NSABP). Vogel VG, et al. JAMA. 2006 Jun 21;295(23):2727-41. doi: 10.1001/jama.295.23.joc60074. Epub 2006 Jun 5. JAMA. 2006. PMID: 16754727 Clinical Trial.

10

Prognostic significance of mammographic density change after initiation of tamoxifen for ER-positive breast cancer.

Nyante SJ, Sherman ME, Pfeiffer RM, Berrington de Gonzalez A, Brinton LA, Aiello Bowles EJ, Hoover RN, Glass A, Gierach GL. Nyante SJ, et al. J Natl Cancer Inst. 2015 Feb 6;107(3):dju425. doi: 10.1093/jnci/dju425. Print 2015 Mar. J Natl Cancer Inst. 2015. PMID: 25663687 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

159 results

Results by year